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ProgressionThe course of HIV-1 infection shows a variety of clinical phenotypes with an important involvement of host
factors. We compare host gene expression patterns in CD3+ T cells from two of these phenotypes: long-term
non-progressor patients (LTNP) and matched control patients with standard HIV disease progression. Array
analysis revealed over-expression of 322 genes in progressors and 136 in LTNP. Up-regulated genes in
progressors were mainly implicated in the regulation of DNA replication, cell cycle and DNA damage stimulus
and mostly localized into cellular organelles. In contrast, most up-regulated genes in LTNP were located at the
plasmatic membrane and involved in cytokine–cytokine receptor interaction, negative control of apoptosis or
regulation of actin cytoskeleton. Regarding gene interactions, a higher number of viral genes interacting with
cellular factors were seen in progressors. Our study offers new comparative insights related to disease status
and can distinguish differentiated patterns of gene expression among clinical phenotypes.ular, Hospital Carlos III, Calle
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The natural course of HIV-1 infection shows variability among
infected individuals. The majority of patients develop AIDS within 7–
10 years after infection but a small fraction (5%), called long-term-
non-progressors (LTNP), stay clinically asymptomatic for years in the
absence of antiretroviral therapy (Pantaleo et al., 1995). The
mechanisms contributing to these different phenotypes of viral
infection are a primary focus of current research in HIV pathogenesis.
Despite great advances in recent years identifying several genetic and
viral factors associated with non-progression (Lama and Planelles,
2007; Saksena et al., 2007), the cause for this lack of progression in
many cases remains unclear. There is consensus, however, that is
governed by multiple factors resulting from the interaction between
HIV and host response to the viral infection. It has been described that
HIV-1 infection has dramatic effects on host T cells physiology (Chan
et al., 2007) with signiﬁcant changes in the pattern of cell gene
expression. The identiﬁcation of genes responsible for this non-progression should provide a valuable approach to understand HIV
pathogenesis.
New high-throughput techniques, like microarray analysis, allow
the management of huge information on gene expression patterns
comparing different groups of samples. Using these methods, various
studies analysed gene expression proﬁles in different cell types
infected with HIV-1 and using in vitro or in vivo approaches (Giri et al.,
2006). However, very few have monitored gene expression in T cells
from patients with different stages of AIDS disease (Hyrcza et al.,
2007; Sankaran et al., 2005; Wu et al., 2008). Most of these later
studies have examined limited number of samples for each group of
patients (5 or less) and in some cases results oblige to combine similar
phenotypes in order to obtain more differently regulated genes
(Hyrcza et al., 2007). Sample size is important to detect not only the
largest changes in the levels of gene expression but also more subtle
differences with any reliability, and also well deﬁne phenotypes are
essential to avoid bias in large scale studies. For this reason, we
decided to focus our analysis in two well deﬁned different groups of
patients with a good sample size in both.
In the current study, we used a well characterized cohort of LTNP
established in 1997 at the Hospital Carlos III (Rodes et al., 2004) to
compare their gene expression proﬁles in CD3+ T cells with those in
typical progressor HIV-1+ patients. Cells were obtained ex vivo from
HIV-1 infected patients presenting these two different clinical
phenotypes.
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Patients
Patient's characteristics at the time of the analysis are described in
detail in Table 1. Sequencing analyses showed all patients carried HIV-
1 subtype B. The majority of patients had a wild type CCR5 genotype
and only 4 LTNPs and 1 progressor had the 32-bp CCR5 deletion in
heterozygosis.
Microarray and differential analysis
RNA from ex vivo CD3+ T cells was used to obtain gene expression
data from Agilent microarrays; witch contained 43,377 probe sets
corresponding to approximately 30,000 genes described for whole
human genome.
Differences in gene expression were measured with a moderated
t-statistic. The t-statistic means have beenmoderated across genes. To
do that, the sample standard deviation is shrunk towards a pooled
standard deviation value using empirical Bayes methods. Data are
presented as progressors versus LTNP gene expression (t=P-LTNP).
The analysis revealed a total of 458 differentially expressed genes
between both groups of patients (see Supplementary data). Whereas
in the progressors’ group 322 genes were up-regulated genes
(t=positive value), only 136 were seen in the non-progressors
(t=negative value), indicating a higher cell activity in more effective
infections and two different patterns of gene expression according to
phenotype.
An overlap analysis of these differentially expressed genes found
in our study with other reported genome-wide analysis and host
factor studies (Brass et al., 2008; König et al., 2008; Zhou et al., 2008;
Bushman et al., 2009) showed 23 coincident genes (gene symbols:
HMGB1, THOC4, SNRPD1, RAD51, RANBP1, SUMO1, FEN1, BAZ2B,
TUBB, NUDT1, SNRPA1, GINS4, PLK1, KIAA1012, MND1, PSMC3,
YWHAQ, MICB, PRKX, SSR1, BCRA1, UBE2C, ASB1).
Functional analysis
Genes operate with an intricate network of interactions within the
cell and in some cases in a redundant manner. Complex traits such
HIV infections are starting to be considered from a system biology
perspective. To facilitate the understanding of the biological implica-
tions of these 458 differential genes, functional analyses using the
FATIGO tool from GEPAS (Al-Shahrour et al., 2005, 2006) were
performed. This tool used gene-ontology and KEGG databases to give
an association between each gene and its function. The distribution of
any combination of terms between two groups of genes can be
simultaneously tested by means of a Fisher's exact test. From this
analysis relevant data on location of the up-regulated genes (known
as cellular component), parts of different biological processes they are
implicated with, molecular functions, or involved metabolic path-
ways, could be obtained.Table 1
Patient's characteristics. Means±SD for age, time of infection, CD4 counts, CD4
percentage and viral load count are provided.
Characteristics Patients (n=30) P value
LTNP
(n=15)
Progressors
(n=15)
Sex (numb. Men) 11 (73%) 13 (86%) 0.379
Age (years) 42.6±5.4 35±8.6 0.007
Time since diagnosis (years) 17.6±4.45 2.4±0.83 b0.001
CD4abs (cell/μL) 638.2±265 488±281 0.146
CD4% 33.6±7.76 24.2±9.95 0.007
Viral load (log RNA copies/mL) 2.99±0.82 4.40±0.81 b0.001Regarding the main localization of differentially expressed genes
between LTNP and progressors, we noticed that despite a wide
distribution of genes in both groups, up-regulated genes in LTNPs
were localized in higher proportion within the plasmatic membrane.
These include GPR15, IL-17RA, BMPR2, among others. Otherwise, up-
regulated genes in progressors were found inside the cell and
principally in the nucleus, associated to chromosomes and with
intracellular organelles (Fig. 1a and Table 2 section a). The location
determines the cell part activated in each case.
For biological processes, some differences emerged in gene
expression between LTNP and progressors that may be relevant to
the progression of the infection. Despite up-regulated cell cycle genes
present in both groups (Fig. 1b and Table 2 section b), there was a
signiﬁcant higher number of expressed genes in progressors, where
the virus has a fairly high replication. In fact, most of the up-regulated
genes in progressors were related to cell cycle, speciﬁcally to the
mitosis phase, nucleic acid metabolic processes and regulation of cell
cycle progression. Furthermore, the remaining up-regulated genes
were related to endogenous stimulus response, more speciﬁcally DNA
damage stimulus and DNA repair. On the other hand, up-regulated
genes in LTNPs were mostly associated with other speciﬁc functions
different than cell cycle. These included cell surface receptor linked
signal transduction, actin cytoskeleton organization and biogenesis, as
well as negative regulation of apoptosis.
When analysing for molecular function most up-regulated genes
were within LTNPs and very few in progressors (Fig. 1c and Table 2
section c). Functions detected were related to ion binding, trans-
membrane receptor and G-protein coupled receptor activities.
Progressors had only up-regulated the nucleic acid binding function.
These results are in agreement with observations above, supporting
the idea that in LTNP there was an activation of membrane signalling
functions, whereas in progressors prevailed the cellular cycle
activities, speciﬁcally replication. By the analysis approach we could
also say that in LTNP the cellular cycle activities were reduced.
Finally, speciﬁcmetabolic pathwayswere analysed using the KEGG
database. In LTNPs activated genes were associated to the cytokine–
cytokine receptor interaction, regulation of actin cytoskeleton and
focal adhesion processes whereas genes from progressors were
mainly related to cell cycle pathway (Fig. 2).
In conclusion, we have seen differential characteristic functions
(focused in different parts of cellular metabolism) from each group.
Mainly, higher signalling between cells seems to be a characteristic
pattern for LTNP, more speciﬁcally the functions of cytokine–cytokine
receptor interaction, negative control of apoptosis or regulation of
actin cytoskeleton. Otherwise, in progressors the cellular cycle seems
to be more active, with an important role of regulation of DNA
replication, cell cycle and DNA damage stimulus.Interactions
Although biological meanings derived from our analyses are
relevant to HIV pathogenesis, in an attempt to further complement
these ﬁndings we performed an HIV–host interaction analysis. Genes
with a signiﬁcant representation in up-regulated functions within
both groups were used to ﬁnd any reported interaction with HIV-1. In
Table 3 the main viral-host interactions are shown. Among LTNPs, tat
and env were the main viral genes involved with up-regulated host
genes, while in progressors there was a greater range of viral genes
involved. In the course of infection, the virus uses the cellular
machinery to its beneﬁts across the interaction of viral and host genes.
Furthermore, accessory proteins appear to be dedicated to various
aspects of evasion from adaptive and innate immunity (Malim and
Emerman, 2008). For this reason, a higher number of viral genes
interacting with cellular factors may be a sign of more advance stage
of infection.
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Fig. 1. Graphic representation of gene distribution in LTNP and progressors. Data are expressed in gene representation percentage annotated for each GO category at different levels:
a) cellular component: differences in localization into the cell; b) biological function: differences in activated biological processes; and c) molecular function: differences in
molecular components.
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Previous reports on gene expression in LTNP patients have
identiﬁed interferon responses as a signature for progression
(Hyrcza et al., 2007) and an up-regulation of components ofMAPK and cytotoxic pathways in LTNP (Wu et al., 2008). However,
a clearer picture of the subversion of cell machinery by HIV in
LTNP is still needed. The goal of our study was to compare the
host-virus interactions between a large series of well deﬁned LTNP
with more than 20 years of follow up in some cases and a group of
Table 2
List of genes expressed in each group of patients and annotated for each GO category.
GO level Location Genes expressed in LTNP Nº
genes
%
LTNP
Genes expressed in progressors Nº
genes
%
progressors
p-
value
a) Cellular component
Level 4 membrane ATP11A, PDPK1, VEZT, SYPL1,
DDEF1, TNFRSF10B, EVI2A, SSR1,
RAB14,SEC23A, GPR15, PIP5K3,
XYLT1, CYSLTR1, AMICA1, ARL6IP5,
IL17RA, SPTLC1, FGFRL1, P2RY5,
RDX, PAG1, MPZL1, HOOK3, DPYD,
IL1RAP, TMEM55A, BMPR2, AFTPH,
TMTC2, PDGFB, C18orf1, EVI2B
33 47.14 BAK1, ITGB1BP1, LAMA5, CBX5, ALS2CR4,
CYP4V2, ZDHHC21, CALM3, PKMYT1, IL12RB1,
TMEFF2, MICB, ARF5, FAM14B, KIRREL2,
ARL6IP1, STOML2, TIMM13, FDXR, COX7C,
TAPBP, TMEM97, CD38, CLDN11, CD8B, IDH2,
PTPRK
27 17.31 b0.001
intracellular C14orf43, FBXO9, SSBP2, EVI5, PDPK1,
VEZT, SYPL1, CHD9, CENTG3, NPEPPS,
TACC1, SSR1, DCK, PITPNC1, RAB14,
SEC23A, BAZ2B, ARID1A, TLE4, ZNF175,
SHOC2, HSD17B4, ZFP1, ROCK1, PIP5K3,
XYLT1, RCOR1, KIAA1012, ARL6IP5,
YTHDC1, SPTLC1, ACO1, RFWD2, RDX,
MDFIC, KLHL5, HOOK3, DPYD, AFTPH,
SH3GL1, TMTC2, KLHL7, GLB1, SGK3,
PTEN, FBXL5, HIPK3, EGLN3, CUL1
49 70 EXO1, SOLH, CIT, FBXO4, RABEP1, CENPM, MVK,
MMAB, SUV39H2, SSBP3, GTSE1, FHL2,
HIST3H2BB, CBX5, EZH2, CYP4V2, CIDEC,
CDCA7, ISG15, THOC4, RANBP1, KIAA1967,
TPX2, GLRX5, GTF3C4, RRM2, PPIH, CHEK1,
CDC45L, FEN1, ROD1, FABP5, CHAF1B,
RAD51AP1, GPS1, FOXM1, MYBL2, ANP32E,
PSMC3, ATP5S, NFEKBIB, CASC5, MAD2L1,
KIAA0101, CALM3, HMGN2, CORT, GINS2, PRR5,
CCNB2, DEPDC1, TIA1, DEPDC1B, ORC1L, GSTZ1,
GINS4, KIFC1, EWSR1, PKMYT1, PPP1CA, E2F7,
TIPIN, TPM4, C16orf33, BRCA1, GMNN,
C6orf173, CXorf26, ORC6L, ATXN10, ARF5, NUF2,
KIF15, TK1, CDC6, DLG7, BUD31, KIF2C, KHSRP,
TROAP, NUCKS1, STMN1, H2AFZ, TFDP1,
HMGB1, ARL6IPI, MIER1, RAD54L, RAD51,
MYL6B, NRL, DAZAP1, ASB1, STOML2, TIMM13,
GSG2, SNRPA1, HNRPA3, FDXR, RECQL4, KIF4A,
MCM5, FRG1, NOLA1, CCNA2, CDCA2, CDCA8,
BIRC5, NUDT21, COX7C, TAPBP, CDT1, TUBB,
HIST1H4D, DNAJC9, NUSAP1, NCAPG, TIMELESS,
SUMO1, ZWILCH, DYNLRB1, RRM1, HMG1L1,
MLF1IP, UBE2N, NCAPH, CENPM, UHRF1, PTTG1,
E2F1, NUDC, NT5C, PLK1, SERBP1, SET, SPC24,
IDH2, ESPL1, NIP7, MCM4
139 89.10 b0.001
Level 5 Plasma
membrane
PDPK1, VEZT, SYPL1, RAB14, GPR15,
PIP5K3, CYSLTR1, IL17RA, FGFRL1,
RDX, MPZL1, IL1RAP, BMPR2, EVI2B
14 21.54 CALM3, IL12RB1, MICB, ARF5, CD38, CLDN11,
CD8B, PTPRK
8 12.16 b0.001
Level 6 intrinsic to
membrane
ATP11A, VEZT, SYPL1, TNFRSF10B,
EVI2A, SSR1, GPR15, XYLT1, CYSLTR1,
AMICA1, ARL6IP5, IL17RA, SPTLC1,
FGFRL1, P2PRY5, PAG1, MPZL1, IL1RAP.
TMEM55A, BMPR2, TMTC2, C18orf1, EVI2B
23 35.38 BAK1, LAMA5, ALS2CR4, CYP4V2, ZDHHC21,
IL12RB1, TMEFF2, MICB, FAM14B, KIRREL2,
ARL6IP1, COX7C, TAPBP, TMEM97, CD38,
CLDN11, CD8B, PTPRK
18 12.16 b0.001
intracellular
organelle
C14orf43, SSBP2, EVI5, PDPK1, VEZT,
SYPL1, CHD9, CENTG3, NPEPPS, TACC1,
SSR1, DCK, RAB14, SEC23A, BAZ2B,
ARID1A, TLE4, ZNF175, HSD17B4, ZFP1,
ROCK1,PIP5K3, XYLT1, RCOR1, KIAA1012,
ARL6IP5, YTHDC1, SPTLC1, RFWD2,
RDX, MDFIC, KLHL5, HOOK3, AFTPH,
TMTC2, KLHL7, GLB1, SGK3, HIPK3, EGLN3
40 61.54 EXO1, CIT, RABEP1, CENPM, MVK, MMAB,
SUV39H2, SSBP3, GTSE1, FHL2, HIST3H2BB,
CBX5, EZH2, CYP4V2, CDCA7, THOC4, RANBP1,
KIAA1967, TPX2, GLRX5, GTF3C4, PPIH, CHEK1,
CDC45L, FEN1, ROD1, CHAF1B, RAD51AP1, GPS1,
FOXM1, MYBL2, ANP32E, PSMC3, ATP5S,
NFKBIB, CASC5, MAD2L1, KIAA0101, HMGN2,
CORT, GINS2, CCNB, TIA1, ORC1L, GSTZ1, GINS4,
KIFC1, EWSR1, PKMYT1, PPP1CA, E2F7, TIPIN,
TPM4 C16orf33, BRCA1, GMNN, C6orf173,
ORC6L, NUF2, KIF15, CDC6, DLG7, BUD31, KIF2C,
KHSRP, NUCKS1, STMN1, H2AFZ, TFDP1,
HMGB1, ARL6IP1, MIER1, RAD54L, RAD51,
MYL6B, NRL, DAZAP1, STOML2, TIMM13, GSG2,
SNRPA1, HNRPA3. FDXR, RECQL4, KIF4A, MCM5,
FRG1, NOLA1, CCNA2, CDC8, BIRC5, NUDT21,
COX7C, TAPBP, CDT1, TUBB, HIST1H4D, DNAJC9,
NUSAP1, NCAPG, TIMELESS, SUMO1, ZWILCH,
DYNLRB1, HMG1L1, MLF1IP, UBE2N, NCAPH,
CENPM, UHRF1, PTTG1, E2F1, NUDC, NT5C,
PLK1, SERBP1, SET, SPC24, IDH2, ESPL1, NIP7,
MCM4
122 82.43 b0.01
Level 7 Intracellular
non-membrane
-bound
organelle
CHD9, ROCK1, RDX, MDFIC,
KLHL55, HOOK3, KLHL7
7 12.07 CIT, CENPN, SUV39H2, GTSE1, HIST3H2BB,
CBX5, RANBP1, TPX2, CHEK1, MYBL2, MAD2L1,
HMGN2, CORT, CCNB2, KIFC1, TPM4, BRCA1,
ORC6L, NUF2, KIF15, CDC6, DLG7, KIF2C, STMN1,
H2AFZ, HMGB1, RAD51, MYL6B, STOML2, KIF4A,
NOLA1, CDCA8, BIRC5, NUDT21, CDT1, TUBB,
HIST1H4D, DNAJC9, NUSAP1, ZWILCH,
DYNLRB1, HMG1L1, MLF1IP, CENPM, NUDC,
PLK1, SPC24, ESPL1
48 34.78 b0.001
intrinsic to
membrane
SYPL1, GPR15, CYSLTR1, IL17RA,
MPZL1, IL1RAP, BMPR2, EVI2B
8 13.79 IL12RB1, CD8B, PTPRK 3 2.17 b0.01
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Table 2 (continued)
GO level Location Genes expressed in LTNP Nº
genes
%
LTNP
Genes expressed in progressors Nº
genes
%
progressors
p-
value
Level 8 nucleus C14orf43, SSBP2, EVI5, VEZT, CHD9,
CENTG3, NPEPPS, TACC1, DCK,
BAZ2B, ARID1A, TLE4, ZNF175,
ZFP1, RCOR1, YTHDC1, RFWD2,
MDFIC, KLHL7, HIPK3, EGLN3
21 42.86 EXO1, CENPN, SUV39H2, SSBP3, FHL2,
HIST3H2BB, CBX5, EZH2, CDCA7, THOC4,
RANBP1, KIAA1967, TPX2, GTF3C4, PPIH, CHEK1,
CDC45L, FEN1, ROD1, CHAF1B, RAD51AP1, GPS1,
FOXM1, MYBL2, ANP32E, PSMC3, NFKBIB,
CASC5, MAD2L1, KIAA0101, HMGN2, CORT,
GINS2, CCNB, TIA1, ORC1L, GINS4, EWSR1,
PPP1CA, E2F7, TIPIN, C16orf33, BRCA1, GMNN,
C6orf173, ORC6L, NUF2, CDC6, DLG7, BUD31,
KIF2C, KHSRP, NUCKS1, H2AFZ, TFDP1, HMGB1,
MIER1, RAD54L, RAD51, NRL, DAZP1, BIRC5,
NUDT21, CDT1, HIST1H4D, NUSAP1, NCAPG,
TIMELESS, SUMO1, HMG1L1, MLF1IP, UBE2N,
NCAPH, CENPM, UHRF1, PTTG1, E2F1, NUDC,
NT5C, PLK1, SERBP1, SET, SPC24, ESPL1, NIP7,
MCM4
96 73.85 b0.001
chromosome CHD9 1 2.04 CENPM, SUV39H2, HIST3H2BB, CBX5, CHEK1,
MYBL2, MAD2L1, HMGN2, CORT, BRCA1, ORC6L,
NUF2, KIF2C, H2AFZ, HMGB1, RAD51, CDCA8,
BIRC5, CDT1, HIST1H4D, ZWILCH, HMG1L1,
MLF1IP, CENPM, SPC24
25 19.23 b0.01
b) Biological processes
Level 3 cell cycle EVI5, TACC1, BMPR2,
PTEN, PDGFB, CUL1
6 8.22 EXO1, MDK, CIT, CKS1B, SUV39H2, GTSE1,
RANBP1, TPX2, CHEK1, CEP55, CDC45L, YWHAQ,
CHAF1B, GPS1, MYBL2, MAD2L1, CCNB2, KIFC1,
PKMYT1, PPP1CA, E2F7, BRCA1, GMNN, NUF2,
KIF15, CDC6, DLG7, KIF2C, MAPK13, STMN1,
TFDP1, UBE2C, RAD51, RAD54L, GSG2, MCM5,
CCNA2, CDCA8, BIRC5, CDT1, PBK, TUBB,
NUSAP1, NCAPG, NCAPH, UHRF1, CDKN3,
PTTG1, E2F1, NUDC, PLK1, SPC24, ESPL1
53 33.12 b0.001
Response to
endogenous stimulus
No genes 0 0 EXO1, GTSE1, CHEK1, FEN1, CHAF1B, RAD51AP1,
BRCA1, HMGB1, RAD51, RAD54L, NUDT1,
C16orf35, TYMS, RECQL4, CCNA2, UBE2N,
UHRF1, PTTG1
139 89.1 b0.001
Level 4 mitotic cell cycle CUL1 1 1.43 CIT, GTSE1, TPX2, CHEK1, CEP55, MAD2L1,
CCNB2, KIFC1, PKMYT1, NUF2, KIF15, CDC6,
DLG7, KIF2C, STMN1, UBE2C, CCNA2, CDCA8,
BIRC5, CDT1, PBK, TUBB, NUSAP1, NCAPG,
NCAPH, CDKN3, PTTG1, E2F1, NUDC, PLK1,
SPC24, ESPL1
32 20.38 b0.001
nucleoside, nucleotide
and nucleic acid
metabolic process
C14orf43, SSBP2, CHD9, DCK,
BAZ2B, ARID1A, TLE4, ZNF175,
ZFP1, RCOR1, YTHDC1, DPYD,
HIPK3
13 18.57 EXO1, SUV39H2, SSBP3, FHL2, HIST3H2BB,
CBX5, EZH2, CDCA7, THOC4, GTF3C4, RRM2,
PPIH, CHEK1, CDC45L, FEN1, ROD1, CHAF1B,
RAD51AP1, FOXM1, MYBL2, CARHSP1, NFKBIB,
HMGN2, GINS2, ORC1L, EWSR1, E2F7, C16orf33,
BRCA1, GMNN, ORC6L, TK1, CDC6, BUD31,
KHSRP, WDR4, DHFR, H2AFZ, TFDP1, HMGB1,
MIER1, RAD54L, RAD51, NRL, NUDT1, GSG2,
C16orf35, SNRPA1, TYMS, HNRPA3, RECQL4,
MCM5, FRG1, NOLA1, CCNA2, NUDT21, CDT1,
HIST1H4D, TIMELESS SUMO1, RRM1, HMG1L1,
MLF1IP, UBE2N, UHRF1, PTTG1, E2F1, NT5C,
SERBP1, SET, MCM4
71 12.16 b0.001
response to DNA
damage stimulus
No genes 0 0 EXO1, GTSE1, CHEK1, FEN1, CHAF1B, RAD51AP1,
BRCA1, HMGB1, RAD54L, RAD51, NUDT1,
C16orf35, TYMS, RECQL4, CCNA2, UBE2N,
UHRF1, PTTG1
18 11.46 b0.01
Level 5 cell surface receptor
linked signal
transduction
PDPK1, TNFRSF10B, TLE4, SHOC2,
GPR15, CYSLTR1, IL17RA, P2RY5,
MPZL1, IL1RAP, BMPR2, DKK3
12 18.18 CALM3, CORT, IL12RB1, CD8B 4 2.61 b0.001
Level 6 DNA repair No genes 0 0 EXO1, CHEK1, FEN1, CHAF1B, RAD51AP1,
BRCA1, HMGB1, RAD54L, RAD51, NUDT1,
C16orf35, TYMS, RECQL4, UBE2N, UHRF1, PTTG1
16 10.74 b0.01
actin ﬁlament-based
process
PDPK1, ROCK1, RDX, KLHL5, PDGFB 5 8.06 MYL6B 1 0.67 b0.01
Level 7 actin cytoskeleton
organization and
biogenesis
PDPK1, ROCK1, RDX, KLHL5, PDGFB 5 10.20 No genes 0 0 b0.01
Level 9 negative regulation
of programmed
cell death
ROCK1, SGK3, PTEN, HIPK3 4 23.53 MYBL2, HMGB1, BIRC5 3 4.29 b0.05
(continued on next page)
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Table 2 (continued)
GO level Location Genes expressed in LTNP Nº
genes
%
LTNP
Genes expressed in progressors Nº
genes
%
progressors
p-
value
regulation of
apoptosis
TNFRSF10B, ROCK1, SGK3, PTEN, HIPK3,
CUL1
6 35.29 BAK1, CIDEC, TRAIP, MYBL2, TIA1, BRCA1,
HMGB1, BIRC5, TUBB, CD38
10 14.29 b0.10
c) Molecular Function
Level 3 ion binding ATP11A, PXDN, DDEF1, CENTG3, NPEPPS,
SSR1, IRF2BP2, SEC23A, BAZ2B, ZNF175,
LTA4H, RNF24, ZFP1, ROCK1, PIP5K3, PJA2,
CENTB2, ACO1, RFWD2, DPYD, BMPR2,
GLB1, EGLN3, SMAP2
24 31.17 SOLH, CIT, SUV39H2, CHI3L2, FHL2, CYP4V2,
ZDHHC21, KIAA1967, RRM2, FEN1, TRAIP,
CALM3, EWSR1, PPP1CA, DOHH, BRCA1,
ZFAND2B, BUD31, MYL6B, TIMM13, GSG2,
RECQL4, BIRC5, UHRF1, NT5C
25 15.53 b0.01
nucleic acid binding C14orf43, SSBP2, CHD9, BAZ2B, ARID1A,
TLE4, PUM2, ZNF175, ZFP1, RCOR1, ACO1,
WDR44
12 15.58 EXO1, SOLH, SSBP3, RDM1, HIST3H2BB, EXH2,
DDX49, THOC4, GTF3C4, FEN1, ROD1,
RAD51AP1, FOXM1, MYBL2, CARHSP1, HMGN2,
TIA1, ORC1L, EWSR1, E2F7, BRCA1, ORC6L,
KIF15, BUD31, KIF2C, KHSRP, H2AFZ, TFDP1,
HMGB1, MIER1, RAD54L, RAD51, NRL, DAZAP1,
SNRPA1, HNRPA3, RECQL4, KIF4A, MCM5,
NOLA1, NUDT21, CDT1, HIST1H4D, HMG1L1,
UHRF1, PTTG1, E2F1, SERBP1, NIP7, MCM4,
50 31.06 b0.05
receptor activity TNFRSF10B, EVI2A, GPR15, CYSLTR1,
IL17RA, FGFRL1, P2RY5, ILRAP, BMPR2
9 11.69 IL12RB1 KIF15 CD38 CD8B PTPRK 5 3.11 b0.05
lipid transporter
activity
ATP11A PITPNC1 HSD17B4 3 3.90 No genes 0 0 b0.05
Level 4 transmembrane
receptor activity
EVI2A GPR15 CYSLTR1 IL17RA FGFRL1
P2RY5 IL1RAP BMPR2
8 12.9 IL12RB1 PTPRK 2 1.47 b0.01
cation binding PXDN DDEF1 CENTG3 NPEPPS SSR1
IRF2BP2 SEC23A BAZ2B ZNF175 LTA4H
RNF24 ZFP1 ROCK1 PIP5K3 PJA2 CENTB2
ACO1 RFWD2 DPYD BMPR2 GLB1 EGLN3
SMAP2
23 37.10 SOLH CIT SUV39H2 CHI3L2 FHL2 CYP4V2
ZDHHC21 KIAA1967 RRM2 FEN1 TRAIP CALM3
EWSR1 PPP1CA DOHH BRCA1 ZFAND2B BUD31
MYL6B TIMM13 RECQL4 BIRC5 UHRF1
23 16.91 b0.01
metal ion binding ATP11A PXDN DDEF1 CENTG3 NPEPPS
SSR1 IRF2BP2 SEC23A BAZ2B ZNF175
LTA4H RNF24 ZFP1 ROCK1 PIP5K3 PJA2
CENTB2 ACO1 RFWD2 DPYD BMPR2 EGLN3
SMAP2
23 37.10 SOLH CIT SUV39H2 FHL2 CYP4V2 ZDHHC21
KIAA1967 RRM2 FEN1 TRAIP CALM3 EWSR1
PPP1CA DOHH BRCA1 ZFAND2B BUD31 MYL6B
TIMM13 GSG2 RECQL4 BIRC5 UHRF1 NT5C
24 17.65 b0.01
Level 5 transition metal ion
binding
PXDN DDEF1 CENTG3 NPEPPS IRF2BP2
SEC23A BAZ2B ZNF175 LTA4H RNF24 ZFP1
ROCK1 PIP5K3 PJA2 CENTB2 ACO1 RFWD2
DPYD BMPR2 EGLN3
20 35.09 SOLH CIT SUV39H2 FHL2 CYP4V2 ZDHHC21
RRM2 FEN1 TRAIP EWSR1 PPP1CA DOHH BRCA1
ZFAND2B BUD31 TIMM13 RECQL4 BIRC5 UHRF1
19 16.69 b0.05
G-protein coupled
receptor activity
GPR15 CYSLTR1 P2RY5 3 5.26 No genes 0 0 b0.05
108 M. Salgado et al. / Virology 411 (2011) 103–112progressors, in an attempt to understand and characterize the
factors associated with different stages of disease. To avoid
masking effects over gene expression, progressors were also
treatment naïve.
HIV infection leads to extensive defects in T cells which play an
important role in its progression rate (Sodora and Silvestri, 2008),
and although cell populations have been extensively characterized,
the genetic bases of interactions in relation to disease progression
are still poorly understood. LTNP maintain a highly functional T-cell
population compared with the majority of HIV-infected patients
(Betts et al., 2006). By using the total T-cell population (CD3+) in
peripheral blood we could obtain a global picture of the differences
in interactions between virus and host cells in these two
phenotypes. In fact, we detected distinct transcriptional features
and 458 highly differential genes between LTNP and progressors.
With the GEPAS analysis we identiﬁed signiﬁcantly expressed gene
sets to further understand their biological mechanism and
relationship within phenotypes. Some of these gene differences
were related to characteristic functions involved in DNA replica-
tion, cell cycle regulation and apoptosis which have been
previously reported in the context of HIV replication (Chun et al.,
2003) and progression (Hyrcza et al., 2007; Wu et al., 2008).
However we have found other non-reported pathways over-
expressed only in one of the studied phenotypes, such as
cytokine–cytokine receptor interaction and regulation of actin
cytoskeleton in LTNPs and response to DNA damage stimulus in
progressors.Differential dysregulation of cell cycle pathways between LTNP and
progressors
It is known that HIV induces modiﬁcations in cell cycle in order
to use it for viral replication and proliferation. These changes are
generated by virus–host–cell interaction, as reported in recent
studies that showed the virus needs around 200 host proteins to
develop infection (Brass et al., 2008; König et al., 2008; Zhou et al.,
2008; Bushman et al., 2009). The relative importance of those
proteins taking part in the disease progression has not been deﬁned
yet. In our study, we observed up-regulated sets of genes related
mainly to the cellular mitosis in patients with an evident progression
of the disease. Similar results had been seen in other tissues like
GALT, where dysregulation of the cell cycle was observed in mucosa
cells of both LTNP and viremic patients (Sankaran et al., 2005). In
our study, however, this cell cycle dysregulation was not evident in
LTNP. It seems that in CD3+ T cells the bulk of up-regulated cell
cycle genes were skewed towards progressor patients which
indicates a more rapid turnover of CD4+ and CD8+ T cells in
progressive infection in agreement with the Hyrcza and colleagues
study (Hyrcza et al., 2007).
According to these data, the most advanced stages of the
infection were accompanied by a higher cell replication which
would lead to disease progression in our control group. A certain
replicative state in the cell is necessary for a productive HIV
infection. However this persistent turnover would disrupt the
immune system organization and loss of targets cells resulting in
Pathways LTNP Genes N  genes % LTNP Progressors Genes N  genes % Progressor pvalue
Cell cycle CUL1 1 4
SKP1 CHEK1 CDC45L YWHAQ MAD2L1 CCNB2 
ORC1L PKMYT1 ORC6L CDC6 TFDP1 MCM5 
CCNA2 PTTG1 E2F1 PLK1 ESPL1 MCM4
18 32,14 <0,01
Cytokine-cytokine 
receptor interaction
TNFRSF10B IL17RA IL1RAP BMPR2 
PDGFB 5 20 IL12RB1 1 1,79 <0,01
Regulation of actin 
cytoskeleton ROCK1 PIP5K3 RDX PDGFB 4 16 PPP1CA 1 1,79 <0,05
Focal adhesion PDPK1 ROCK1 PTEN PDGFB 4 16 LAMA5 PPP1CA 2 3,57 <0,10
b) KEGG pathways
a) Kegg pathways
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Fig. 2. a) Graphic representation of gene distribution in LTNP and progressors according to KEEG PATHWAYS. b) List of expressed genes in LTNP or progressors related to each studied
pathway.
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replication observed in LTNP would beneﬁt those patients with a
low frequency of infection and a lesser effect over the immune
system function. The virus has a target selectivity (CCR5+ CD4+
memory T cells), and an inappropriate activation state may result
in too little expression of CCR5 in cell surface to become infected
(Grossman et al., 2006). Moreover, the proportion of LTNP patients
with Delta32 mutation in CCR5 is higher than progressors in our
population which may contribute to lower the source of viral
production.Table 3
Host–viral gene interactions in LTNP and progressors.
Group Up-regulated host
gene
Viral gene Main effects
LTNP bmpr2 tat Tat downregulates Bmpr
pten tat Pten enhances Tat
cul1 tat Cul1 is in a complex pathway of
Tat
tnfrsf10B env
(gp120)
Gp120 upregulate trail
TNFRS10B
gpr15 env
(gp120)
Gp120 activates Gpr15
Progressors rad51 tat Rad51 enhances Tat
tat Tat upregualates Rad51
vpr Vpr inhibits Rad51
integrase Rad51 inhibits HIV integration
kif4 gag Pr55(Gag) binds KIF4
cd8b nef Nef downregulates CD8b
brca1 vpr Vpr stimulates Brca1
cd38 env
(gp120)
Gp120 interacts with CD38Higher number of genes related to response to DNA damage stimulus in
progressors vs. LTNP
HIV-1, like other viruses with distinct replication strategies,
activates DNA damage response pathways. It seems activation of
cellular DNA repair and recombination enzymes is beneﬁcial for viral
replication (Sinclair et al., 2006).
Here we found up-regulated genes in the progressors’ group
involved in DNA repair and response to DNA damage stimulus,
whereas no genes related to this function were up-regulated in LTNPs.
Therefore, these signals may correlate with higher replication but the
role of them in the viral pathogenesis is not well known.
Recently, it has been shown that DNA repair proteins are necessary
to early steps in the virus life cycle (König et al., 2008); speciﬁcally,
cellular DNA repair machinery has been implicated in playing critical
roles in viral DNA integration and the completion of viral DNA
synthesis after integration (Goff, 2007). Otherwise, activation of DNA
damage response pathways can also promote apoptosis (Sinclair et al.,
2006; Corbeil et al., 2001). In fact, two of the genes obtained from the
analysis (GTSE1 and BRCA1) are associated with P53 protein, which is
activated in HIV-1-induced apoptosis as shown in a recent in vitro
study (Imbeault et al., 2009). In our study, some genes related to the
activation of apoptosis are expressed in progressors but not very
strongly. For this reason, DNA repair could indicate here a stabilization
of proviral integration more than cellular death.
Increased regulation of actin cytoskeleton in LTNP patients
Host cell microﬁlament cytoskeleton plays a wide range of roles in
HIV-1 infection, including viral entry, reverse transcription, transport
to the nucleus, integration and ﬁnally a correct budding and release
from the cell (Fackler and Krausslich, 2006). However, the interaction
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polymerization of actin is required for viral binding and entry but
inhibits some subsequent steps by acting as a physical barrier for the
virus. To overcome this barrier and continue with the viral cycle, a
protein known as coﬁlin is activated to depolymerize actin (Liu et al.,
2009; Bukrinsky, 2008).
In our study, we observed a higher expression of genes related to
actin cytoskeleton organization and biogenesis in the group of LTNPs,
many of them related to phosphorylation of coﬁlin which renders it
inactive and prevents its association with actin. In LTNPs an excess of
the G-actin form as a result of low depolymerization could block the
virus trafﬁcking through the cell. Normally, the virus is capable to
modulate and use the microtubules net for its own ends (Fackler and
Krausslich, 2006; Lu et al., 2008) by means of viral proteins such as
Nef, Gag or Tat which interact with the cytoskeleton (Campbell et al.,
2004; Matarrese and Malorni, 2005; Naghavi and Goff, 2007). In our
group of LTNP both gag-p24 and nef gene sequences were character-
ized (data no shown) and except for one patient (deleted Nef), the
rest carried complete genes with, in appearance, conserved functional
domains. However, without functional experiments we cannot
discard differences in modulation of actin with respect to Nef or Gag
from progressors as well as Tat proteins.
On the other hand, the increase in expression of these genes
subsequent to viral infection may be associated with transmembrane
events of viral binding and entry and other structural events involved
with cellular activation and signalling (Vahey et al., 2002). When we
studied the speciﬁc function of most up-regulated genes, we saw they
were also associated with adhesion processes, so another explanation
for non-progression could be that in these patients there is a higher
and better immunological synapsis between antigen speciﬁc CD8+ T
cells and infected CD4+ T cells due to an adhesion processes and
remodelling cytoskeleton take place in the synapsis (Shen et al.,
2005). At this point, we cannot distinguish whether up-regulation of
the cytoskeletal proteins in LTNP decants towards a better immune
response or maintenance of the physical intracellular barrier.
Up-regulation of genes related to cytokine–cytokine receptor interaction
in LTNPs
A successful immune response depends upon the ability of T-
lymphocytes to respond to antigenic stimulation by cellular activa-
tion. This activation results in a cascade of cytokine secretion, receptor
up-regulation, cellular proliferation and development of effector
functions (Smith et al., 1980).
In our study, activated cell surface receptors linked to signal
transduction are observed in LTNPs. The identiﬁed genes included
cytokine receptors such as IL17RA, IL1RAP or TNFRSF1 which may be
part of a stronger, more preserved and protective immune response in
this group of patients. IL-17RA controls the activity of IL-17A which
regulates the expansion of Th17 CD4+ cell subset (Wright et al., 2008;
Smith et al., 2008). A recent study found that HIV-1-speciﬁc IL-17-
producing CD4+ T cells were reduced or non-detected in LTNP (Yue
et al., 2008) which would support our observation. Also data from our
lab show a negative correlation between IL-17RA expression and viral
load (unpublished data). Others have seen that the imbalance
between Th17 cells with other T cells seems to be predictive of
disease progression in SIV infection (Cecchinato et al., 2008; Favre
et al., 2009) which points out to the equilibrium between pro- and
anti-inﬂammatory responses as a critical factor to distinguish
between pathogenic and non-pathogenic infections. IL-1RAP is
essential for IL-33 induced T-cell activation and involved in innate
cellular immune responses (Ali et al., 2007), while TNFRSF1 would
be involved in the regulation of apoptosis.
Previously, it was shown that viral suppression in LTNPs may
result from efﬁcient maintenance of CD4+ T helper and HIV-1-
speciﬁc CD8+T-cell responses in both gut-associated lymphoid tissue(GALT) and circulating lymphocyte (Sankaran et al., 2005). In
agreement with this observation, our LTNP patients have activated
adhesion molecules and cytokine receptors that could relate to an
active immunological synapsis and a more efﬁcient T-cell response
respectively. Otherwise, some of these molecules can play other
functions related to viral pathogens. An example is Gpr15 (up-
regulated in LTNP) which has been shown as an active coreceptor for
viral entrance of HIV-2 (Blaak et al., 2005). Some of the patients in our
study have 32-bp deletion in the CCR5. The up-regulation of Gpr15
can also compensate for a defective CCR5 although with less efﬁcacy;
and which may inﬂuence by reducing viral ﬁtness. More studies are
needed to conﬁrm this hypothesis.
Differences across patterns of expression for apoptosis
It has been reported that LTNP patients present a low level of
apoptosis and a consequent reduced rate of CD4+ loss likely
accompanied by low viral burden or by the presence of a defective
virus (Franceschi et al., 1997; Kirchhoff et al., 1995). In our study, both
groups have activated genes related to apoptosis and differences
between groups did not reach a strong statistical signiﬁcance.
However, different patterns of apoptosis gene expression can be
glimpsed with a trend towards inhibition in LTNP and activation in
controls; the ratio negative/positive apoptosis regulatory genes were
higher in LTNP. On the contrary, progressors presented up-regulated
genes like CD38, described to have a strong relationship with
activation and cell death. These results are in full accordance with
previous studies showing CD38 expression on CD8+ T cells as a
marker associated with HIV disease progression (Liu et al., 1997). In a
recent report (Jiao et al., 2008), the activation level of CD8+ T cells,
especially CD38 expression, correlated inversely with CD4+ T cell
counts and positively with HIV-1 RNA loads in typical progressors.
Activated genes for positive regulation of apoptosis in progressors are
in agreement with other activated functions in this group such as cell
cycle and DNA replication, whichwere implicated in several pathways
linked with cellular death. T-cell apoptosis is thought to be one
strategy by which HIV-1 evades host immune supervision.
Genome-wide analyses are important to enrich the list of factors in
the HIV–host interaction in order to identify new candidates for HIV
therapeutics. Overall, the results in this study offer new comparative
insights related to disease status and can distinguish differentiated
patterns of gene expression between HIV+LTNP and progressor
patients. The most notable features are the preserved regulation of
cytoskeleton and cell signalling functions in LTNP and a profound
dysregulation of cell cycle in progressors. Many of the genes identiﬁed
will further facilitate the understanding of genetic basis of progressive
and non-progressive disease.
Materials and methods
Patients
Fifteen LTNPs from the Hospital Carlos III cohort and 15
Progressors were studied. LTNP were deﬁned at the time of cohort
inclusion as HIV-1+ individuals with more than 10 years of infection
(since diagnosis), CD4 counts above 500 cells/μL and naïve for ART. At
the time of microarray analysis all of them had viral loads (VL) under
10,000 copies/mL and three of them were considered “elite
controllers” (Deeks and Walker, 2007). Typical progressor HIV-1+
patients were, at the time of study, drug-naïve individuals with less
than 5 years of HIV infection after diagnosis and a CD4 decline higher
than 80 cells/μl per year. Two years after sample collection, 13 out of
15 progressors (86%) have initiated HAART therapy. A signed
informed consent was obtained from participants in accordance
with the hospital's Ethic Committee.
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Nef and gag genes from viruses infecting each patient were RT-PCR
ampliﬁed and sequenced using an ABI 3100 genetic analyzer.
Phylogenetic analyses were performed in ampliﬁed sequences using
phylip package. Presence of Delta-32 mutation in CCR5 gene was
analysed by PCR in all patients.
Microarray analysis and statistical analysis
Extended experimental conditions are described in supplementary
material. Brieﬂy, PBMC of the HIV-1 infected individuals were
obtained and CD3+ cells were isolated from them. The purity of
isolated CD3+ cells was measured by ﬂow cytometry and in all
instanceswas above 95%. Puriﬁed T cells were lysed and total RNAwas
extracted, ampliﬁed and hybridized to Whole Human Genome
Microarray 4 × 44K (G4112F, Agilent Technologies). Data was edited
and analysed using R (R Development Core team, 2006) and speciﬁc
packages of the Bioconductor project. To examine genes that were
differentially expressed under different conditions, we used the linear
modeling features of the Bioconductor limma package (Smyth, 2005)
http://www.bioconductor.org/. This package also uses empirical
Bayes methods (Smyth, 2004) that permit the use of moderated t
statistics, and it also incorporates statistical tools to adjust for the
multiplicity of the tests. To test the differences between progressors
(P) and non-progressors (NP) subjects, the following linear model
was ﬁtted to the data:
yij = τi + eij
where yij is the observation corresponding to status i on individual j, τi
is the effect of the ith status (P and NP) and eij is the experimental
error, assumed to be independently normally distributed with 0mean
and varianceσe2. The differentially expressed genes due to differences
in the status were discovered by establishing the null hypothesis of no
differences between status estimates τi for each gene. With the aim to
span a broad number of up-regulated genes within phenotype, a cut-
off of 0.15 was established based in the false discovery rate (FDR)
(adjusted P value by Benjamini and Hochberg's method (BH)). From
differentially expressed genes we studied the biological meaning by
GEPAS package (Al-Shahrour et al., 2005, 2006). Interaction analyses
between HIV-1 and host genes were done using the HIV-1, Human
Protein Interaction database (NCBI) (Fu et al., 2009).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.037.
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